Celldex Therapeutics Reports 78% Revenue Decline and Increased Operating Losses for Fiscal Year 2025

Celldex Therapeutics, Inc. reported a significant decline in financial performance for the fiscal year ended December 31, 2025, with total revenues of $1.5 million, a decrease of 78% from $7.0 million in 2024. The revenue drop was primarily attributed to a substantial reduction in contracts and grants revenue, which fell from $7.0 million to $1.4 million, largely due to decreased services performed under agreements with Rockefeller University. In contrast, revenue from product development and licensing agreements increased to $97,000 from $13,000 in the previous year. The company incurred an operating loss of $287.4 million, a 47% increase from the prior year's loss of $195.1 million, driven by a 50% rise in research and development expenses, which totaled $245.1 million.

In terms of operational developments, Celldex is focusing on advancing its lead drug candidate, barzolvolimab (CDX-0159), which is currently in Phase 3 clinical trials for chronic spontaneous urticaria (CSU). Enrollment for these trials was completed in February 2026, with topline data expected in the fourth quarter of 2026. The company also initiated a Phase 3 study for cold urticaria and symptomatic dermographism in December 2025, following positive results from earlier Phase 2 studies. Additionally, Celldex is expanding its pipeline with CDX-622, a bispecific antibody targeting chronic inflammation, which is currently in Phase 1 trials.

The company reported an increase in its employee headcount to 198 as of December 31, 2025, with 166 employees engaged in research and development activities. This increase reflects Celldex's commitment to expanding its clinical development capabilities. The company also noted that it has cash, cash equivalents, and marketable securities totaling $518.6 million, which it believes will be sufficient to fund operations through 2027, although it may need to raise additional capital to meet long-term liquidity needs.

Looking ahead, Celldex anticipates continued operating losses as it invests heavily in the development of its drug candidates. The company plans to explore various avenues for raising capital, including potential licensing agreements, business combinations, and public offerings. The future success of Celldex will depend on its ability to navigate the complexities of clinical trials, secure regulatory approvals, and ultimately achieve market acceptance for its therapies. The company remains focused on its mission to develop innovative treatments for patients with severe inflammatory and allergic diseases, despite the challenges it faces in the competitive biopharmaceutical landscape.